Chang CO, Figueredo VK, Murillo PTJ

Language: Spanish
References: 21
Page: 1-9
PDF size: 355.30 Kb.

ABSTRACT

Introduction: Hypercholesterolemia is associated with cardiovascular diseases in the elderly population and, also, with risk factors such as age, life expectancy, and functional capacity. Aging as a social transformation of the twenty-first century constitutes an epidemiological situation related with the risk factors for cardiovascular disease. They are classified as modifiable (high blood pressure, high cholesterol levels, smoking, obesity) and non-modifiable (age, sex, family history). Smoking potentiates this disease, as does high blood pressure by multiplying functional limitations.
Objective: To describe hypercholesterolemia as a cardiovascular risk factor in older adults.
Methods: A bibliographic review study was carried out through systematic consultation of articles and books published in electronic databases such as PubMed, Scielo, Dialnet, Cochrane plus, Redalyc, Elsevier, in addition to national and international organizations, during the period from January to June 2019. In order to search for the information, health descriptors were used, such as hipercolesterolemia [hypercholesterolemia], adulto mayor [older adults], factores de riesgo [risk factors], together with the Boolean operator and. We also consulted websites such as the Organization for Economic Cooperation and Development, Cardiovascular disease and diabetes, American Diabetes Association, Cardiovascular Disease and Risk Management.
Conclusions: Hypercholesterolemia is a modifiable risk factor; therefore, it is recommended to establish prevention strategies that modify the lifestyle of the older adults positively. Furthermore, statins should be used in doses of low to moderate intensity, considering the pharmacological interactions and adverse effects, as well as presence of comorbidities and life expectancy.

REFERENCES

1. Galvis Pérez Y, Barona Acevedo J, Cardona-Arias JA. Prevalencia de dislipidemias en una institución prestadora de servicios de salud de Medellín (Colombia), 2013. Rev CES Med. 2016 [acceso: 16/04/2019];30(1):3-13. Disponible en: Disponible en: http://www.scielo.org.co/pdf/cesm/v30n1/v30n1a01.pdf

2. Organización Mundial de la Salud, Observatorio Mundial de la Salud (GHO). Colesterol elevado. Situación y tendencias. 2015 [acceso: 02/03/2019]. Disponible en Disponible en http://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/

3. Arellano O, Barquera S, Barriguete J, Lara A, López A, Rosas M. Protocolo clínico para el diagnóstico y tratamiento de las Dislipidemias. CENAPRECE, Secretaria de Salud, D.F. México. 2da. ed. 2011 [acceso: 20/06/2016]. Disponible en: Disponible en: http://www.cenaprece.salud.gob.mx/programas/interior/adulto/descargas/pdf/ProtocoloClinico_diagnós tico_tratamiento_dislipidemias.pdf

4. Ajufo E, Rader DJ. Recent advances in the pharmacological management of hypercholesterolaemia. Lancet Diabetes Endocrinol. 2016 [acceso: 16/04/2019];4(5):436-46. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27012540

5. Anderson TJ, Mancini GB, Genest J Jr, Grégoire J, Lonn EM, Hegele RA. The new dyslipidemia guidelines: what is the debate? Can J Cardiol. 2015 [acceso: 16/04/2019];31(5):605-12. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25816728

6. Bays HE. A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment. J Clin Lipidol. 2016 [acceso: 16/04/2019];10(2):228-39. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27055954

7. Bays HEE, Jones PH, Orringer CE, Brown WV, Jacobson TA. National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol. 2016 [acceso: 16/04/2019];10(1 Suppl):S1-S43. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26891998

8. Ble A, Hughes PM, Delgado J, Masoli JA, Bowman K, Zirk-Sadowski J, et al. Safety and Effectiveness of Statins for Prevention of Recurrent Myocardial Infarction in 12 156 Typical Older Patients: A Quasi-Experimental Study. J Gerontol A Biol Sci Med Sci. 2017 [acceso: 04/06/2019];72(2):243-50. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27146371

9. Artiles L. Metodología de la Investigación para las Ciencias de la Salud. La Habana: Editorial Ciencias Médicas; 2009 [acceso: 04/06/2019]. Disponible en: Disponible en: http://files.sld.cu/ortopedia/files/2017/12/Metodolog%C3%ADa-de-la-investigaci%C3%B3n.pdf

10. Hernández Sampieri R. Metodología de la Investigación. 6ta. ed. México DF: Interamericana Editores, SA. DE C.V; 2014 [acceso: 04/06/2019]. Disponible en: Disponible en: https://periodicooficial.jalisco.gob.mx/sites/periodicooficial.jalisco.gob.mx/files/metodologia_de_la_investigacion_-_roberto_hernandez_sampieri.pdf

11. Naciones unidas. Envejecimiento. 2017 [acceso: 04/06/2019]. Disponible en: Disponible en: https://www.un.org/es/sections/issues-depth/ageing/index.html

12. Ruiz Rivera Laura. La hipercolesterolemia como factor de riesgo cardiovascular. Universidad Sevilla. 2016 [acceso: 19/04/2019]. Disponible en: Disponible en: https://idus.us.es/.../LA%20HIPERCOLESTEROLEMIA%20COMO%20FACTOR%20

13. Bou Malham S, Goldberg AC. Cardiovascular risk reduction: the future of cholesterol lowering drugs. Curr Opin Pharmacol. 2016 [acceso: 19/04/2019];27:62-9. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26939026

14. OECD. Organization for Economic Cooperation and Development. Cardiovascular disease and diabetes: Policies for better health and quality of care. In series: OECD Health Policies Studies. 2015 [acceso: 19/06/2016]. Disponible en: Disponible en: http://www.oecd.org/health/cardiovascular-diseaseand-diabetes-policies-for-better-health-and-quality-of-care-9789264233010-en.htm

15. Serra Valdés Miguel. Las enfermedades crónicas no transmisibles: una mirada actual ante el reto. Rev. Finlay. 2016 [acceso: 19/04/2019];6(2):167-9. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2221-24342016000200009&lng=es

16. Casado T, Campos LM, Moron F, Solis José. Perfil lipídico en mayores de 65 años.: Prevalencia de hipercolesterolemia y factores de riesgo cardiovascular. Rev Med Hered. 1996 [acceso: 19/04/2019];7(3):125-31. Disponible en: Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1018-130X1996000300005&lng=es

17. ADA. American Diabetes Association. Cardiovascular Disease and Risk Management. Diabetes Care. 2016 [acceso: 19/04/2019];39(Suppl 1):S1-S2. Disponible en: Disponible en: https://care.diabetesjournals.org/content/suppl/2015/12/21/39.Supplement_1.DC2/2016-Standards-of-Care.pdf

18. Rosenson RS. Treatment of lipids (including hypercholesterolemia) in secondary prevention. 2016 [acceso: 15/06/2016]. Disponible en: Disponible en: https://www.uptodate.com/contents/management-of-low-density-lipoprotein-cholesterol-ldl-c-in-the-secondary-prevention-of-cardiovascular-disease?search=treatment-of-lipids-including-hypercholesterolemia-in-secondary-prevention&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

19. Soto KA, Loza O, García N, Rodríguez KG, Sánchez-Reyesb L, Fanghänel G. Estatinas en adultos mayores, una población creciente. Revista de la Facultad de Medicina de La Universidad Nacional Autónoma de México (UNAM). 2013 [acceso: 15/06/2016];56(1). Disponible en: Disponible en: http://www.scielo.org.mx/pdf/facmed/v56n1/v56n1a3.pdf

20. Michael w. Rich. Respuesta de Michael W. Rich. Journal of American Geriatrics society. 2014 [acceso: 15/06/2016];62(5). Disponible en: Disponible en: http://www.sagg.org.ar/wp/wp-content/uploads/2016/06/Dr.-Golan-2013-2014.pdf

21. Grupo de Trabajo de Atención al Mayor de la semFYC. Atención a las personas mayores desde la atención primaria. Sociedad Española de Medicina de Familia y Comunitaria. semfyc ediciones. Barcelona. 2016 [acceso: 19/04/2019]. Disponible en: Disponible en: https://www.semfyc.es/wp-content/uploads/2016/05/Atencion-a-las-personas-mayores.pdf